quantisnow
FeedTopReportsPricing
⌘K
Live feed
13:17:00·128d
PRRelease
AIM ImmunoTech Inc. logo
ArriVent BioPharma Inc. logo
Halozyme Therapeutics Inc. logo
+2

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B

AIM· AIM ImmunoTech Inc.AVBP· ArriVent BioPharma Inc.HALO· Halozyme Therapeutics Inc.MRUS· Merus N.V.ONCY· Oncolytics Biotech Inc.
Health Care
Original source

Companies

  • AIM
    AIM ImmunoTech Inc.
    Health Care
  • AVBP
    ArriVent BioPharma Inc.
    Health Care
  • HALO
    Halozyme Therapeutics Inc.
    Health Care
  • MRUS
    Merus N.V.
    Health Care
  • ONCY
    Oncolytics Biotech Inc.
    Health Care

Recent analyst ratings

  • Mar 12AVBPUpdateBTIG Research$42.00
  • Dec 10AVBPUpdateBTIG Research$45.00
  • Dec 4HALOUpdateGoldman$56.00
  • Nov 25AVBPUpdateTruist$43.00
  • Oct 14HALOUpdateLeerink Partners$70.00
  • Sep 17MRUSUpdateBarclays$112.00

Related

  • PR7d
    AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
  • PR10d
    AIM ImmunoTech Provides Routine Update on Annual Filings
  • SEC13d
    AIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  • SEC13d
    SEC Form 424B5 filed by AIM ImmunoTech Inc.
  • PR14d
    AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
  • SEC15d
    SEC Form F-10POS filed by Oncolytics Biotech Inc.
  • SEC15d
    SEC Form F-10POS filed by Oncolytics Biotech Inc.
  • SEC15d
    SEC Form F-10POS filed by Oncolytics Biotech Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022